ArticleHemaSphere2025
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with
Abstract read
In one paragraph
Article in HemaSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Comparative efficacy and long-term survival of CD19/22 versus CD19 CAR-T immunotherapy in Relapsed/Refractory B-ALL with TP53 alterations.Journal of translational medicine · 2026Trial
- ELN vs. IPSS-M in MDS/AML: Which Prognostic System Should Guide Clinical Decision-Making?Cancers · 2026Review
- The Amyloid State of Mutant p53 in Cancer.JMA journal · 2026Review
- Article
- Revisiting tumor immunogenicity through the lens of mutant p53: Implications for cancer immunotherapy.Apoptosis : an international journal on programmed cell death · 2026Review
- Metabolism and Immunity-Adapted Radiotherapy (M.I.A.R): A Conceptual Framework for Overcoming the Therapeutic Plateau in Clinical Radiotherapy.Current oncology (Toronto, Ont.) · 2026Review
- Article
- Wild-Type p53 Protein Enhances APR-246-Induced Cytotoxicity in Acute Myeloid Leukemia and Normal Hematopoietic Stem/Progenitor Cells.International journal of molecular sciences · 2026Article
- The MDM2-p53 Axis in Osteosarcoma: Current Understanding of Regulatory Mechanisms and Targeted Therapeutic Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage Model.Genes · 2026Article
- Single-cell profiling reveals reprogrammed hierarchy and disrupted immune-stromal ecosystem in TP53-mutated AML.Experimental hematology & oncology · 2026Article
- [Chinese expert consensus on the clinical application of next-generation sequencing technology in myelodysplastic neoplasms (2026)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a comprehensive overview of targeted approaches.Frontiers in oncology · 2026Review
- Functional heterogeneity of TP53 mutants in venetoclax-resistant AML: mechanisms, clinical implications, and therapeutic opportunities.Frontiers in oncology · 2026Review
- The role and therapeutic potential of nanotechnology-mediated ferroptosis regulation in myelodysplastic syndromes.Frontiers in oncology · 2026Review
- Bioengineering Strategies to Address Key Bottlenecks in Ferroptosis-Based Cancer Therapy: A Critical Review.International journal of nanomedicine · 2026Review
- Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies.Current hematologic malignancy reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
David A SallmanMalignant Hematology Department H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA.ORCID https://orcid.org/0000-0003-0504-8233
Rami S KomrokjiMalignant Hematology Department H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA.ORCID https://orcid.org/0000-0002-1876-5269
Amy E DezernSidney Kimmel Comprehensive Cancer Center Johns Hopkins University Baltimore Maryland USA.
Marie SebertGroupe Francophone de Myelodysplasies, GFM Paris France.
Guillermo Garcia-ManeroDepartment of Leukemia MD Anderson Cancer Center Houston Texas USA.
Ramy RahméGroupe Francophone de Myelodysplasies, GFM Paris France.
Eric S WinerDana Farber Cancer Institute Boston Massachusetts USA.
Jacqueline Lehmann-CheMolecular, Oncology Unit, Hospital Saint Louis, APHP Université Paris Cité Paris France.
Gail J RobozWeill Cornell Medicine and the New York Presbyterian Hospital New York New York USA.
Isabelle MadelaineMolecular, Oncology Unit, Hospital Saint Louis, APHP Université Paris Cité Paris France.
Mikkael A SekeresSylvester Cancer Center, Division of Hematology University of Miami Miami Florida USA.
Pierre PeterlinGroupe Francophone de Myelodysplasies, GFM Paris France.
Onyee ChanMalignant Hematology Department H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA.
Odile Beyne-RauzyGroupe Francophone de Myelodysplasies, GFM Paris France.
Andrew KuykendallMalignant Hematology Department H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA.
Christian RecherGroupe Francophone de Myelodysplasies, GFM Paris France.
Amy McLemoreMalignant Hematology Department H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA.
Aspasia StamatoullasHematology Department Centre Henri Becquerel Rouen France.
Ling ZhangMalignant Hematology Department H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA.
Lise WillemsGroupe Francophone de Myelodysplasies, GFM Paris France.
Qianxing MoDepartment of Biostatistics & Bioinformatics H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA.
Emmanuel RaffouxGroupe Francophone de Myelodysplasies, GFM Paris France.
Lisa NardelliMalignant Hematology Department H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA.
Céline BerthonGroupe Francophone de Myelodysplasies, GFM Paris France.
Najla H Al AliMalignant Hematology Department H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA.
Bruno QuesnelGroupe Francophone de Myelodysplasies, GFM Paris France.
Eric PadronMalignant Hematology Department H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA.
Hagop M KantarjianDepartment of Leukemia MD Anderson Cancer Center Houston Texas USA.
Alan F ListStelexis New York New York USA.
Lionel AdesGroupe Francophone de Myelodysplasies, GFM Paris France.
Jeffrey E LancetMalignant Hematology Department H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA.
Pierre FenauxGroupe Francophone de Myelodysplasies, GFM Paris France.
Thomas CluzeauGroupe Francophone de Myelodysplasies, GFM Paris France.ORCID https://orcid.org/0000-0002-6745-1127
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.